Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135497114> ?p ?o ?g. }
- W2135497114 endingPage "141" @default.
- W2135497114 startingPage "126" @default.
- W2135497114 abstract "Experimental autoimmune encephalomyelitis (EAE) is a widely used model of multiple sclerosis (MS) and both conditions have been reported to exhibit reduced endocannabinoid activity. The purpose of this study was to address the effect of exogenously administered 2-arachidonoylglycerol (2AG), an endocannabinoid receptor ligand, on acute phase and chronic disability in EAE. Acute and chronic EAE models were induced in susceptible mice and 2AG-treatment was applied for 14 days from day of disease induction. 2AG-treatment ameliorated acute phase of disease with delay of disease onset in both EAE models and reduced disease mortality and long-term (70 days post-induction) clinical disability in chronic EAE. Reduced axonal pathology in the chronic EAE- (p < 0.0001) and increased activation and ramification of microglia in the 2AG-treated acute EAE- (p < 0.05) model were noticed. The latter was accompanied by a 2- to 4-fold increase of the M2-macrophages in the perivascular infiltrations (p < 0.001) of the 2AG-treated animals in the acute (day 22), although not the chronic (day 70), EAE model. Expression of cannabinoid receptors 1 (CB1R) and 2 (CB2R) was increased in 2AG-treated animals of acute EAE vs. controls (p < 0.05). In addition, ex vivo viability assays exhibited reduced proliferation of activated lymph node cells when extracted from 2AG-treated EAE animals, whereas a dose-dependent response of activated lymphocytes to 2AG-treatment in vitro was noticed. Our data indicate for the first time that 2AG treatment may provide direct (via CBRs) and immune (via M2 macrophages) mediated neuroprotection in EAE." @default.
- W2135497114 created "2016-06-24" @default.
- W2135497114 creator A5003765997 @default.
- W2135497114 creator A5005399318 @default.
- W2135497114 creator A5014241454 @default.
- W2135497114 creator A5014403258 @default.
- W2135497114 creator A5015804063 @default.
- W2135497114 creator A5050618709 @default.
- W2135497114 creator A5054166902 @default.
- W2135497114 creator A5059420988 @default.
- W2135497114 creator A5064361318 @default.
- W2135497114 creator A5065631892 @default.
- W2135497114 creator A5067517361 @default.
- W2135497114 creator A5073327452 @default.
- W2135497114 creator A5074387178 @default.
- W2135497114 date "2011-05-01" @default.
- W2135497114 modified "2023-10-17" @default.
- W2135497114 title "Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis" @default.
- W2135497114 cites W1556717980 @default.
- W2135497114 cites W1558851717 @default.
- W2135497114 cites W1559076309 @default.
- W2135497114 cites W1629776612 @default.
- W2135497114 cites W1967922769 @default.
- W2135497114 cites W1972403397 @default.
- W2135497114 cites W197245174 @default.
- W2135497114 cites W1975111987 @default.
- W2135497114 cites W1976127510 @default.
- W2135497114 cites W1978924462 @default.
- W2135497114 cites W1979203254 @default.
- W2135497114 cites W1982731273 @default.
- W2135497114 cites W1987163810 @default.
- W2135497114 cites W1989073099 @default.
- W2135497114 cites W1991497324 @default.
- W2135497114 cites W1998171066 @default.
- W2135497114 cites W1999203299 @default.
- W2135497114 cites W2002201669 @default.
- W2135497114 cites W2004485518 @default.
- W2135497114 cites W2005479057 @default.
- W2135497114 cites W2007485514 @default.
- W2135497114 cites W2008863207 @default.
- W2135497114 cites W2009825695 @default.
- W2135497114 cites W2018740189 @default.
- W2135497114 cites W2018810438 @default.
- W2135497114 cites W2022980251 @default.
- W2135497114 cites W2024335876 @default.
- W2135497114 cites W2024653583 @default.
- W2135497114 cites W2027483802 @default.
- W2135497114 cites W2032715817 @default.
- W2135497114 cites W2037750523 @default.
- W2135497114 cites W2041788967 @default.
- W2135497114 cites W2042094529 @default.
- W2135497114 cites W2043884829 @default.
- W2135497114 cites W2046136399 @default.
- W2135497114 cites W2049544736 @default.
- W2135497114 cites W2050453710 @default.
- W2135497114 cites W2054248285 @default.
- W2135497114 cites W2055309785 @default.
- W2135497114 cites W2056188558 @default.
- W2135497114 cites W2057976080 @default.
- W2135497114 cites W2060589571 @default.
- W2135497114 cites W2075894678 @default.
- W2135497114 cites W2077030928 @default.
- W2135497114 cites W2077322233 @default.
- W2135497114 cites W2080185710 @default.
- W2135497114 cites W2081232028 @default.
- W2135497114 cites W2083158204 @default.
- W2135497114 cites W2085741941 @default.
- W2135497114 cites W2089573633 @default.
- W2135497114 cites W2092038789 @default.
- W2135497114 cites W2097251306 @default.
- W2135497114 cites W2097717578 @default.
- W2135497114 cites W2098025305 @default.
- W2135497114 cites W2101898118 @default.
- W2135497114 cites W2101958789 @default.
- W2135497114 cites W2103477492 @default.
- W2135497114 cites W2103617764 @default.
- W2135497114 cites W2104696504 @default.
- W2135497114 cites W2104731491 @default.
- W2135497114 cites W2107286202 @default.
- W2135497114 cites W2108885138 @default.
- W2135497114 cites W2113319670 @default.
- W2135497114 cites W2122672927 @default.
- W2135497114 cites W2124248227 @default.
- W2135497114 cites W2126304984 @default.
- W2135497114 cites W2146904199 @default.
- W2135497114 cites W2149381430 @default.
- W2135497114 cites W2152856916 @default.
- W2135497114 cites W2160612029 @default.
- W2135497114 cites W2161204141 @default.
- W2135497114 cites W2166889498 @default.
- W2135497114 cites W2171403507 @default.
- W2135497114 cites W2470586538 @default.
- W2135497114 cites W4252049794 @default.
- W2135497114 doi "https://doi.org/10.1016/j.brainres.2011.03.020" @default.
- W2135497114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21406188" @default.
- W2135497114 hasPublicationYear "2011" @default.
- W2135497114 type Work @default.
- W2135497114 sameAs 2135497114 @default.